scholarly journals Tuberculosis drug resistance in Canada, 1998 to 2000

2001 ◽  
Vol 12 (3) ◽  
pp. 141-143
Author(s):  
Melissa D Phypers ◽  
Linda Panaro ◽  
Penny Nault
Keyword(s):  
World Health ◽  
Drug Resistant ◽  
First Line ◽  
International Union ◽  
The World ◽  
Resistant Strains ◽  
Health Organization ◽  
Global Threat ◽  
Drug Resistant Strains ◽  
And Control

The emergence of drug-resistant strains of tuberculosis (TB) is a global threat to TB prevention and control efforts. A recent study conducted by the World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease found strains of TB resistant to first-line anti-TB drugs in all countries surveyed (1). The WHO estimates that 50 million people are infected with strains of drug-resistant TB (2).

Drug-resistant tuberculosis: World Health Organization launches Global Response Plan 2007-2008

2007 ◽  
Vol 12 (27) ◽  
Author(s):  
Collective Editorial team
Keyword(s):  
World Health ◽  
Drug Resistant ◽  
First Line ◽  
Global Response ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Resistant Strains ◽  
Response Plan ◽  
Health Organization ◽  
Drug Resistant Strains

An increasing proportion of tuberculosis (TB) cases today are resistant to first line, and often also to second line anti-TB drugs. Drug-resistant strains of Mycobacterium tuberculosis are now responsible for over 400,000 cases of TB per year.

scholarly journals Semi-Synthesis of Marine-Derived Ilamycin F Derivatives and Their Antitubercular Activities

2021 ◽  
Vol 9 ◽  
Author(s):  
Jun Li ◽  
Zhiyong Liu ◽  
Mingye Hong ◽  
Changli Sun ◽  
Tianyu Zhang ◽  
...  
Keyword(s):  
Prevention And Control ◽  
Inhibitory Concentration ◽  
Drug Resistant ◽  
Structure Activity ◽  
The World ◽  
Resistant Strains ◽  
New Challenges ◽  
Low Cytotoxicity ◽  
Drug Resistant Strains ◽  
And Control

Tuberculosis (TB) is still a global disease threatening people’s lives. With the emergence of multi-drug-resistant Mycobacterium tuberculosis the prevention and control of tuberculosis faces new challenges, and the burden of tuberculosis treatment is increasing among the world. Ilamycins are novel cyclopeptides with potent anti-TB activities, which have a unique target protein against M. tuberculosis and drug-resistant strains. Herein, ilamycin F, a major secondary metabolite isolated from the marine-derived mutant strain Streptomyces atratus SCSIO ZH16 ΔilaR, is used as a scaffold to semi-synthesize eighteen new ilamycin derivatives (ilamycin NJL1–NJL18, 1–18). Our study reveals that four of ilamycin NJLs (1, 6, 8, and 10) have slightly stronger anti-TB activities against Mtb H37Rv (minimum inhibitory concentration, 1.6–1.7 μM) compared with that of ilamycin F on day 14th, but obviously display more potent activities than ilamycin F on day 3rd, indicating anti-TB activities of these derivatives with fast-onset effect. In addition, cytotoxic assays show most ilamycin NJLs with low cytotoxicity except ilamycin NJL1 (1). These findings will promote the further exploration of structure-activity relationships for ilamycins and the development of anti-TB drugs.

Management of Multidrug-Resistant Tuberculosis

2018 ◽  
Vol 39 (03) ◽  
pp. 310-324 ◽  
Author(s):  
Jose Caminero ◽  
Charles Daley
Keyword(s):  
Multidrug Resistant ◽  
New Drugs ◽  
World Health ◽  
Drug Resistant ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Mdr Tb ◽  
Resistant Strains ◽  
Health Organization ◽  
Drug Resistant Strains

AbstractDrug-resistant strains of Mycobacterium tuberculosis pose a major threat to global tuberculosis control. Despite the availability of curative antituberculosis therapy for nearly half a century, inappropriate and inadequate treatment of tuberculosis, as well as unchecked transmission of M. tuberculosis, has resulted in alarming levels of drug-resistant tuberculosis. The World Health Organization (WHO) estimates that there were 600,000 cases of multidrug-resistant tuberculosis (MDR-TB)/rifampin-resistant (RR) tuberculosis in 2016, defined as strains that are resistant to at least isoniazid and rifampicin. Globally, WHO estimates that 4.1% of new tuberculosis cases and 19% of retreatment cases have MDR-TB. By the end of 2016, 123 countries had reported at least one case of extensively drug-resistant strains, which are MDR-TB strains that have acquired additional resistance to fluoroquinolones and at least one second-line injectable. It is estimated that only 22% of all MDR-TB cases are currently receiving therapy. This article reviews the management of MDR/RR-TB and updates recommendations regarding the use of shorter course regimens and new drugs.

Pharmacogenetics of Metformin

2021 ◽  
Vol 1 (6) ◽  
pp. 123-129
Author(s):  
Alrahman Joneri
Keyword(s):  
American Diabetes Association ◽  
Glucose Utilization ◽  
Medical Condition ◽  
World Health ◽  
First Line ◽  
Glucose Levels ◽  
Normal Limits ◽  
The World ◽  
Health Organization ◽  
The Individual

Hyperglycemia is a medical condition in which an increase in glucose levels in the blood exceeds normal limits. Hyperglycemia is one of the typical signs of diabetes mellitus (DM). The World Health Organization (WHO) predicts an increase in the number of people with DM which is a global health threat. Diabetes is the leading cause of kidney failure, and the leading cause of heart disease and stroke, in adults. Metformin, which is a biguanide group, is recommended by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes as the first-line oral therapy for DM and is the most widely used oral medication worldwide. Metformin can also increase peripheral glucose utilization and ultimately decrease the production of fatty acids and triglycerides. Some of the individual differences that underlie the variation in response to metformin.

scholarly journals Partisipasi Dalam Pencegahan Dan Penanggulangan Covid-19

2021 ◽  
Vol 4 (4) ◽  
pp. 941-953
Author(s):  
Dyan Kunthi Nugrahaeni ◽  
Novie Elvinawaty Mauliku ◽  
Budiman Budiman ◽  
Gunawan Irianto ◽  
Arina Novilla
Keyword(s):  
World Health Organization ◽  
Diagnostic Test ◽  
Rapid Diagnostic Test ◽  
Community Service ◽  
Prevention And Control ◽  
Community Services ◽  
World Health ◽  
The World ◽  
Health Organization ◽  
And Control

ABSTRAK The World Health Organization menetapkan outbreak SARS-CoV-2 sebagai Kedaruratan Kesehatan Masyarakat yang Meresahkan Dunia dan dinyatakan sebagai pandemik. Penyebaran dan penularan penyakit Coronavirus Disease-19 (COVID-19) sangat tinggi, dengan jumlah penderita lebih dari 117 juta di seluruh dunia. Diperlukan berbagai strategi dan tindakan yang dapat dilakukan untuk pencegahan, penanggulangan dalam rangka mengatasi COVID-19. Tujuan Pengabdian masyarakat yang dilakukan oleh Stikes Achmad Yani adalah ikut berperan serta dalam pencegahan dan penanggulangan COVID-19 di wilayah Kota Cimahi dan Kota Bandung. Metode yang digunakan adalah partisipatori dalam berbagai aktifias pencegahan dan penanggulangan COVID-19. Kegiatan Pengabdian Masyarakat yang dilakukan selama pandemic COVID-19 diantaranya adalah demontrasi pembuatan handsanitizer, penyemprotan disinfektan, mengirimkan tim relawan pemeriksaan Rapid Diagnostic Test (RDT) antibodi Cluster Lembang dan relawan Check Point pada kegiatan Pembatasan Sosial Berskala Besar di Kota Bandung. Pemberian donasi kepada masyarakat terdampak pandemik COVID-19 dan donasi Alat Pelindung Diri (APD) ke fasilitas pelayanan kesehatan seperti Rumah Sakit dan Puskesmas. Pelaksanaan Rapid Test Diagnostic (RTD) antibodi dan RTD antigen bagi mahasiswa, dosen dan Karyawan. Stikes Achmad Yani juga berperan serta dalam gebyar Vaksin COVID-19 bagi tenaga kesehatan dan mengirimkan relawan sebagai vaksinator yang diselenggarakan oleh Rumah Sakit Hasan Sadikin berkerjasama dengan PPNI. Partisipasi Stikes Achmad Yani Cimahi dalam berbagai kegiatan yang terkait dengan COVID-19 diharapkan dapat memberikan kontribusi dalam rangka pencegahan penularan, pengendalian dan penanggulangan COVID-19. Kata Kunci: COVID-19, disinfeksi, relawan, Rapid Diagnostic Test  ABSTRACT The World Health Organization recognize the SARS-CoV-2 outbreak as a public health emergency of Internasional Concerns and declared it as a pandemic. The spread and transmission of Coronavirus Disease-19 (COVID-19) are very high and reported that over 117 million people have been sufferers worldwide. Several strategies and actions can be carried out to prevention, controlling and overcoming COVID-19. The purpose of community service carried out by Stikes Achmad Yani is to participate in the prevention and control of COVID-19 in Cimahi and Bandung district. The methode used in community services are participatory methods in several activities for prevention and control of COVID-19. Community Service activities carried out during the COVID-19 pandemic included demonstrations of making hand sanitizers, spraying disinfectants, sending a team of volunteers to examine the Rapid Diagnostic Test (RDT) antibody for the Lembang Cluster, and volunteer Check Points at Large-Scale Social Restrictions activities in Bandung. Providing donations to people affected by the COVID-19 pandemic and donations of Personal Protective Equipment (PPE) to health service facilities such as hospitals and health centers. Implementation of Rapid Diagnostic Test (RTD) antibody and RDT antigen for students, lecturers, and staff. Stikes Achmad Yani also participated in the COVID-19 Vaccine for health workers and sent volunteers as vaccinators organized by Hasan Sadikin Hospital in collaboration with PPNI. The participation of Stikes Achmad Yani Cimahi in various activities to contribute prevention of disease transmission and controlling COVID-19. Kata Kunci: COVID-19, disinfection, volunteer, Rapid Diagnostic Test

scholarly journals Coronavirus Disease 2019 Occupational Considerations for Surgeons: A Review Article

2021 ◽  
Vol 10 (1) ◽  
pp. 36-41
Author(s):  
Seyed Hesamaddin Banihashemi ◽  
Ahmadreza Karimi ◽  
Hasti Nikourazm ◽  
Behnaz Bahmanyar ◽  
Dariush Hooshyar
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
World Health Organization ◽  
Medical Staff ◽  
Review Article ◽  
World Health ◽  
Published Data ◽  
Rapid Spread ◽  
The World ◽  
Health Organization ◽  
And Control

The severe acute respiratory syndrome coronavirus 2 virus and its associated disease, called coronavirus disease 2019 (COVID-19), first appeared in Wuhan, China in December 2019 and quickly spread around the world. Coronavirus was officially named COVID-19 by the World Health Organization and was recognized as a pandemic due to its rapid spread worldwide. Based on the published data, it is hoped to provide a source for later studies and to help prevent and control the contagious COVID-19 and its characteristics, and considerations that surgeons and medical staff must observe during the epidemic.

scholarly journals What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae ?

2009 ◽  
Vol 7 (47) ◽  
pp. 905-919 ◽  
Author(s):  
Caroline Colijn ◽  
Ted Cohen ◽  
Christophe Fraser ◽  
William Hanage ◽  
Edward Goldstein ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Infectious Diseases ◽  
Multiple Infection ◽  
Drug Resistant ◽  
Host Interactions ◽  
Resistant Strains ◽  
Neutral Models ◽  
Drug Resistant Strains ◽  
And Control

The rise of antimicrobial resistance in many pathogens presents a major challenge to the treatment and control of infectious diseases. Furthermore, the observation that drug-resistant strains have risen to substantial prevalence but have not replaced drug-susceptible strains despite continuing (and even growing) selective pressure by antimicrobial use presents an important problem for those who study the dynamics of infectious diseases. While simple competition models predict the exclusion of one strain in favour of whichever is ‘fitter’, or has a higher reproduction number, we argue that in the case of Streptococcus pneumoniae there has been persistent coexistence of drug-sensitive and drug-resistant strains, with neither approaching 100 per cent prevalence. We have previously proposed that models seeking to understand the origins of coexistence should not incorporate implicit mechanisms that build in stable coexistence ‘for free’. Here, we construct a series of such ‘structurally neutral’ models that incorporate various features of bacterial spread and host heterogeneity that have been proposed as mechanisms that may promote coexistence. We ask to what extent coexistence is a typical outcome in each. We find that while coexistence is possible in each of the models we consider, it is relatively rare, with two exceptions: (i) allowing simultaneous dual transmission of sensitive and resistant strains lets coexistence become a typical outcome, as does (ii) modelling each strain as competing more strongly with itself than with the other strain, i.e. self-immunity greater than cross-immunity. We conclude that while treatment and contact heterogeneity can promote coexistence to some extent, the in-host interactions between strains, particularly the interplay between coinfection, multiple infection and immunity, play a crucial role in the long-term population dynamics of pathogens with drug resistance.

scholarly journals TB Elimination Requires Discovery and Development of Transformational Agents

2020 ◽  
Vol 10 (7) ◽  
pp. 2605 ◽  
Author(s):  
Christian Lienhardt ◽  
Mario C. Raviglione
Keyword(s):  
Rapid Detection ◽  
Susceptibility Testing ◽  
Drug Susceptibility ◽  
Drug Susceptibility Testing ◽  
New Drugs ◽  
World Health ◽  
Drug Resistant ◽  
The World ◽  
Health Organization ◽  
Combination Regimens

The World Health Organization (WHO) End Tuberculosis (TB) Strategy has set ambitious targets to reduce 2015 TB incidence and deaths by 80% and 90%, respectively, by the year 2030. Given the current rate of TB incidence decline (about 2% per year annually), reaching these targets will require new transformational tools and innovative ways to deliver them. In addition to improved tests for early and rapid detection of TB and universal drug-susceptibility testing, as well as novel vaccines for improved prevention, better, safer, shorter and more efficacious treatments for all forms of TB are needed. Only a handful of new drugs are currently in phase II or III clinical trials, and a few combination regimens are being tested, mainly for drug-resistant TB. In this article, capitalising on an increasingly rich medicine pipeline and taking advantage of new methodological designs with great potential, the main areas where progress is needed for a transformational improvement of treatment of all forms of TB are described.

Sign in / Sign up

Export Citation Format

Share Document